Medical Marijuana: From MAPS

MAPS' mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.

Breaking News: Federal Committee Blocks

Study of Marijuana for Vets with PTSD

October 4, 2011

Dear Gary,
Less than three months ago, our planned study of marijuana for veterans with PTSD made national headlines with a hopeful article in The New York Times ("Marijuana may be studied for combat disorder", July 18, 2011).

We need your support to turn psychedelics and marijuana into prescription medicines.

Make a Contribution

Last weekend, the Washington Post continued the trend of positive media coverage with an exposé about the federal government's refusal to sell us marijuana for the planned study ("Marijuana study of traumatized vets stuck in regulatory limbo", October 1, 2011).
The US Food and Drug Administration cleared the study on April 28, but that didn't stop the Department of Health and Human Services from blocking the study by refusing to sell us the marijuana we require to conduct it. HHS oversees the National Institute on Drug Abuse, which has a monopoly on the supply of marijuana for research in the US.
NIDA's monopoly on marijuana for research serves only to delay and obstruct vital research into marijuana's therapeutic benefits. Pressure is building against the NIDA monopoly, but meanwhile our study is at a standstill and veterans continue to suffer.
See MAPS' official press release for more about the federal obstruction of medical marijuana research, and learnwhy MAPS is taking the DEA to federal court.
Want to get more involved? Join leading medical marijuana researchers and activists at Cartographie Psychedelica this December for panels, lectures, and an all-day workshop on the implications of MAPS' medical marijuana research efforts for science, public health, and human rights.

For science and compassion,